Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

EARLY CAREER INVOLVEMENT

213 - INNOVATION PLENARY: HOW CARDIOLOGY'S FUTURE UNFOLDS

Friday, October 25, 2024
8:30 AM – 9:30 AM PT
Room: 205-207
On-Demand Early Career Involvement
"How Cardiology's Future Unfolds: Navigating Trends in Cardiac Imaging, Electrophysiology, and Cardiac Interventions for the Next Five Years"

4 Topic areas: CNCT - SPECT/CT PET, Echo CMR / CVMRI, Cath/Intervention and New ablation technologies.

These topical presentations will wrap up with a panel discussion and Q&A from the audience.

Check out the latest CCS journals article collection on Innovations

Learning Objectives:

At the end of this session participants will be able to:
  • analyze the latest advancements in cardiovascular imaging, electrophysiology (EP), and cardiac intervention expected to shape the field over the next five years;
  • evaluate how evolving guidelines, reimbursement models, and patient expectations will influence the practice landscape in various cardio subspecialties, empowering attendees to anticipate and adapt to forthcoming changes; and
  • summarize the interactive discussions and knowledge-sharing among participants to collectively anticipate challenges and opportunities in their respective subspecialties, fostering a collaborative environment for strategic planning and professional growth.
Disclosure(s):
Chi-Ming Chow, MD MSc FRCPC FCCS: Khure Health: Consultant/Advisory Board (Ongoing); Podcast AI: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Usqaure Soft Inc.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Shamal Khattak: No financial relationships to disclose
Benjamin J. Chow, MD FRCPC FACC FASNC FSCCT: Atrya: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); TD Bank: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Michael Chetrit, MD FRCPC: Alnylam: Honoraria (Ongoing); BMS: Small Grant for QI (Ongoing), Speaker Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Hororaria (Ongoing), Small grant for research (Ongoing)
Atul Verma, MD FRCPC FHRS: Abbott: Pre-clinical work (Ongoing); Biosense Webster: Advisory board (Ongoing), IIS grant (Ongoing); Medtronic: Advisory board (Ongoing), IIS grant (Ongoing)
Shamir R. Mehta, MD: Abbott: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bristol-Myers Squibb: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Noronordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)
Diamond Fernandes: Heart Fit Clinic: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing)
Mina Madan, MD, MHS, FRCPC, FSCAI: Medtronic Canada: Consultant (Ongoing); Novo Nordisk: Research and Clinical Trial Leadership (Ongoing)